Dr. Vidya Velagapudi

Dr. Vidya Velagapudi, Associate Director, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden


Vidya Velagapudi obtained her Bachelors in Bioscience (1999), Masters in Biotechnology (2001), Advanced PG diploma in Bioinformatics (2002), and then joined Dr.Reddy’s Pharmaceutical company as a Research Associate (2002) in India. Later on she moved to Germany in 2003 for her graduate studies and obtained Ph.D in Applied Biochemistry from the University of Saarland in collaboration with the Max-Planck Institute for Informatics, Saarbrucken.

Dr. Velagapudi then moved to Finland and joined a Biotech CRO, VTT Oy as a Post-doctoral fellow (2006) in collaboration with University of Cambridge, UK, and continued as a Research Scientist and Project Manager (2007-2009). Dr. Velagapudi acted as Director of the national Metabolomics core facility at the Institute for Molecular Medicine Finland FIMM (2010-2019). Dr. Velagapudi was also affiliated to University of Helsinki as an Adjunct Professor (2012-2019) and Principal Investigator at the Faculty of Medicine (2016-2019), and Chair of the Metabolomics Platforms in Biocenter Finland and HiLIFE (2017-2019). Dr. Velagapudi then moved to Sweden and currently working as Associate Director at AstraZeneca since 2019.

Dr. Velagapudi has published around 60 scientific articles in reputed journals and given over 30 invited talks in international scientific events and conferences. Dr. Velagapudi was an invited Metabolomics technology expert for an interview (2014) and spotlight article contributor (2016) at MetaboNews Letter, and international organising committee member for the Metabolomics Society 13th annual conference, Australia, and Precision Medicine workshop in 14th annual conference, The Netherlands. Dr. Velagapudi acted as Finnish ambassador for ELIXIR Metabolomics community, a member of Metabolomics quality assurance and control consortium (mQACC), and an invited reviewer for Marie-Curie fellowships, H2020 and other funding proposals and core facilities.


Please feel free to share this...